Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$572M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$495M |
| 3 |
iShares MBS ETF
MBB
|
+$405M |
| 4 |
Procter & Gamble
PG
|
+$365M |
| 5 |
Microsoft
MSFT
|
+$327M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$605M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$544M |
| 3 |
Sempra
SRE
|
+$474M |
| 4 |
CELG
Celgene Corp
CELG
|
+$411M |
| 5 |
BPL
Buckeye Partners, L.P.
BPL
|
+$380M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 8.85% |
| 2 | Healthcare | 5.77% |
| 3 | Financials | 5.26% |
| 4 | Consumer Discretionary | 4.71% |
| 5 | Communication Services | 4.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2376
NMI Holdings
NMIH
$3.36B
| $3.52M | ﹤0.01% |
106,203
+29,839
| +39% | +$932K |
|
|
AKS
2377
DELISTED
AK Steel Holding Corp
AKS
| $3.52M | ﹤0.01% |
1,071,365
-197,158
| -16% | -$547K |
|
|
PRFT
2378
DELISTED
Perficient Inc
PRFT
| $3.52M | ﹤0.01% |
76,388
-138,158
| -64% | -$5.63M |
|
|
NVRO
2379
DELISTED
NEVRO CORP.
NVRO
| $3.52M | ﹤0.01% |
29,936
+983
| +3% | +$97.4K |
|
2380
Nektar Therapeutics
NKTR
$2.58B
| $3.51M | ﹤0.01% |
10,837
-22,229
| -67% | -$6.45M |
|
2381
CALL
Zimmer Biomet
ZBH
$18.4B
| $3.5M | ﹤0.01% |
24,102
+16,171
| +204% | +$2.23M |
|
|
JJS
2382
DELISTED
iPath Series B Bloomberg Softs Subindex Total ReturnSM ETN
JJS
| $3.5M | ﹤0.01% |
83,000
| – | – |
|
2383
CNO Financial Group
CNO
$5.1B
| $3.5M | ﹤0.01% |
192,854
+91,817
| +91% | +$1.56M |
|
2384
SLM Corp
SLM
$5.15B
| $3.5M | ﹤0.01% |
392,546
+32,784
| +9% | +$285K |
|
2385
PUT
Interactive Brokers
IBKR
$39.8B
| $3.49M | ﹤0.01% |
299,200
+35,600
| +14% | +$418K |
|
2386
Cavco Industries
CVCO
$4.55B
| $3.48M | ﹤0.01% |
17,836
+4,304
| +32% | +$844K |
|
2387
Encore Capital Group
ECPG
$2.13B
| $3.48M | ﹤0.01% |
98,534
+9,660
| +11% | +$338K |
|
2388
PUT
Automatic Data Processing
ADP
$108B
| $3.48M | ﹤0.01% |
20,400
-600
| -3% | -$99.3K |
|
2389
CALL
Take-Two Interactive
TTWO
$46.1B
| $3.48M | ﹤0.01% |
28,400
-32,000
| -53% | -$3.9M |
|
2390
PUT
Edwards Lifesciences
EW
$51.7B
| $3.48M | ﹤0.01% |
44,700
+27,900
| +166% | +$2.18M |
|
|
IMMU
2391
CALL
DELISTED
Immunomedics Inc
IMMU
| $3.47M | ﹤0.01% |
164,200
-5,500
| -3% | -$97K |
|
|
SNV
2392
DELISTED
Synovus
SNV
| $3.47M | ﹤0.01% |
88,591
-69,560
| -44% | -$2.56M |
|
|
INVX
2393
Innovex International
INVX
$1.97B
| $3.47M | ﹤0.01% |
74,014
+28,819
| +64% | +$1.32M |
|
2394
CALL
Clorox
CLX
$12.7B
| $3.47M | ﹤0.01% |
22,600
-7,300
| -24% | -$1.09M |
|
|
DBD
2395
CALL
DELISTED
Diebold Nixdorf Incorporated
DBD
| $3.45M | ﹤0.01% |
327,000
-68,800
| -17% | -$611K |
|
2396
CALL
American Electric Power
AEP
$68.4B
| $3.45M | ﹤0.01% |
36,500
-5,500
| -13% | -$508K |
|
2397
PUT
Wingstop
WING
$3.18B
| $3.45M | ﹤0.01% |
40,000
| – | – |
|
|
AVNS
2398
DELISTED
Avanos Medical
AVNS
| $3.45M | ﹤0.01% |
102,254
+77,759
| +317% | +$2.82M |
|
2399
PUT
Williams-Sonoma
WSM
$29.6B
| $3.44M | ﹤0.01% |
93,800
-45,400
| -33% | -$1.58M |
|
2400
Range Resources
RRC
$8.95B
| $3.44M | ﹤0.01% |
709,997
-70,205
| -9% | -$283K |
|
Similar funds
Barclays's Q4 2019 Portfolio in Review
As of Q4 2019, Barclays held 7,254 positions worth $180B, up 13% from $160B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Barclays deployed $6.1B of net new capital in Q4 2019, opening 260 new positions and adding to 3,541 existing holdings. Its largest new stake was Pacer iPath Gold ETNs: 1,000,000 shares worth $25.3M.
By sector, the portfolio is most concentrated in Technology at 8.9% of assets, up from 7.7% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Invesco QQQ Trust, an estimated $605M trimmed.
- Barclays's largest Q4 2019 buy was Pacer iPath Gold ETNs: 1,000,000 shares worth $25.3M.
- Barclays added most to Apple in Q4 2019, an estimated $572M increase.
- Barclays's biggest Q4 2019 reduction was Invesco QQQ Trust, cutting an estimated $605M.
- Barclays fully exited Celgene Corp in Q4 2019, selling an estimated $411M.
- Barclays's ten largest holdings make up 26% of its $180B portfolio in Q4 2019.
- Barclays opened 260 new positions and closed 700 in Q4 2019.
- Barclays's portfolio value rose 13% quarter-over-quarter to $180B.
Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.